In vitro enzyme inhibition and in vivo anti-hyperuricemic potential of eugenol: an experimental approach

References

• Liu N, Xu H, Sun Q, et al. The role of oxidative stress in hyperuricemia and xanthine oxidoreductase (XOR) inhibitors. Oxid Med Cell Longev. 2021;2021:1470380.
   PubMedGoogle Scholar
• Li L, Zhang Y, Zeng C. Update on the epidemiology, genetics, and therapeutic options of hyperuricemia. Am J Transl Res. 2020;12:3167–3181.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Nagoshi T, Yoshii A, et al. Xanthine oxidase inhibition attenuates doxorubicin-induced cardiotoxicity in mice. Free Radic Biol Med. 2021;162:298–308.
   PubMedGoogle Scholar
• Sakti AS, Widyastanto H, Maulidina A, et al. Xanthine oxidase inhibitory activity of methanol extract fractions of various Indonesian ethnopharmacological plants. Int J Appl Pharm. 2020;12:43–46.
   Google Scholar
• Pacher P, Nivorozhkin A, Szabó C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006;58(1):87–114.
   PubMed Web of Science ®Google Scholar
• El-Tantawy WH. Natural products for the management of hyperuricaemia and gout: a review. Arch Physiol Biochem. 2021;127(1):61–72.
   PubMed Web of Science ®Google Scholar
• Eleleemy M, Amin B, Nasr M, et al. A succinct review on the therapeutic potential and delivery systems of eugenol. Arch Pharm Sci Ain Shams Univ. 2020;4(2):290–311.
   Google Scholar
• Kimenis AA, Vitolina RO, Petersone IO, et al. Pharmacological and toxicological properties of ryodipine. Arzneimittelforschung. 1985;35:672–679.
   PubMedGoogle Scholar
• Abdullah ML, Hafez MM, Al-Hoshani A, et al. Anti-metastatic and anti-proliferative activity of eugenol against triple negative and HER2 positive breast cancer cells 11 medical and health sciences 1112 oncology and carcinogenesis. BMC Complement Altern Med. 2018;18(1):321.
   PubMed Web of Science ®Google Scholar
• Ulanowska M, Olas B. Biological properties and prospects for the application of eugenol—a review. Int J Mol Sci. 2021;22(7):3671.
   PubMedGoogle Scholar
• Binu P. Protective effects of eugenol against hepatotoxicity induced by arsenic trioxide: an antileukemic drug. Iran J Med Sci. 2018;43:305–312.
   PubMed Web of Science ®Google Scholar
• Vijeesh V, Jisha N, Vysakh A, et al. Interaction of eugenol with xanthine oxidase: multi spectroscopic and in silico modelling approach. Spectrochim Acta A Mol Biomol Spectrosc. 2021;258:119843.
   PubMedGoogle Scholar
• Zhang C, Zhang G, Pan J, et al. Galangin competitively inhibits xanthine oxidase by a ping-pong mechanism. Food Res Int. 2016;89(Pt 1):152–160.
   PubMedGoogle Scholar
• Lin S, Zhang G, Pan J, et al. Deciphering the inhibitory mechanism of genistein on xanthine oxidase in vitro. J Photochem Photobiol B. 2015;153:463–472.
   PubMed Web of Science ®Google Scholar
• Wan Y, Zou B, Zeng H, et al. Inhibitory effect of verbascoside on xanthine oxidase activity. Int J Biol Macromol. 2016;93(Pt A):609–614.
   PubMedGoogle Scholar
• Kovalenko YL, Melekhovets OK, Melekhovets Lu V. Estimation of the influence of photobiomodulation on the endothelial function in patients with arterial hypertension under the conditions of hyperuricemia. Photobiol Photomed. 2019;28:9–15.
   Google Scholar
• Wang X-H, Jiang W-R, Zhang M-Y, et al. The visceral fat area to leg muscle mass ratio is significantly associated with the risk of hyperuricemia among women: a cross-sectional study. Biol Sex Differ. 2021;12(1):17.
   PubMedGoogle Scholar
• Gao Z, Zuo M, Han F, et al. Renal impairment markers in type 2 diabetes patients with different types of hyperuricemia. J Diabetes Investig. 2019;10(1):118–123.
   PubMedGoogle Scholar
• Desideri G, Castaldo G, Lombardi A, et al. Is it time to revise the normal range of serum uric acid levels? Eur Rev Med Pharmacol Sci. 2014;18:1295–1306.
   PubMed Web of Science ®Google Scholar
• Watanabe S, Kawano T, Horino T, et al. Influence of hyperuricemia treatment on postoperative acute kidney injury among hyperuricemia patients: a single-center retrospective database analysis. BMC Res Notes. 2019;12(1):756.
   PubMedGoogle Scholar
• Rahmani B, Patel S, Seyam O, et al. Current understanding of tumor lysis syndrome. Hematol Oncol. 2019;37(5):537–547.
   PubMedGoogle Scholar
• Kaneko K, Aoyagi Y, Fukuuchi T, et al. Total purine and purine base content of common foodstuffs for facilitating nutritional therapy for gout and hyperuricemia. Biol Pharm Bull. 2014;37(5):709–721.
   PubMed Web of Science ®Google Scholar
• Bjornstad P, Lanaspa MA, Ishimoto T, et al. Fructose and uric acid in diabetic nephropathy. Diabetologia. 2015;58(9):1993–2002.
   PubMed Web of Science ®Google Scholar
• Choi YJ, Shin HS, Choi HS, et al. Uric acid induces fat accumulation via generation of endoplasmic reticulum stress and SREBP-1c activation in hepatocytes. Lab Invest. 2014;94(10):1114–1125.
   PubMed Web of Science ®Google Scholar
• King C, Lanaspa MA, Jensen T, et al. Uric acid as a cause of the metabolic syndrome. Contrib Nephrol. 2018;192:88–102.
   PubMed Web of Science ®Google Scholar
• Mehta SK, Nayeem N. Natural xanthine oxidase inhibitors for management of gout: a review. Res Rev J Med Health Sci. 2014;3:4–13.
   Google Scholar
• Fais A, Era B, Asthana S, et al. Coumarin derivatives as promising xanthine oxidase inhibitors. Int J Biol Macromol. 2018;120(Pt A):1286–1293.
   PubMedGoogle Scholar
• Yan J, Zhang G, Hu Y, et al. Effect of luteolin on xanthine oxidase: inhibition kinetics and interaction mechanism merging with docking simulation. Food Chem. 2013;141:2766–2773.
   Google Scholar
• Abdou A, Elmakssoudi A, El Amrani A, et al. Recent advances in chemical reactivity and biological activities of eugenol derivatives. Med Chem Res. 2021;30(5):1011–1030.
   Web of Science ®Google Scholar
• Nagababu E, Lakshmaiah N. Inhibition of xanthine oxidase–xanthine–iron mediated lipid peroxidation by eugenol in liposomes. Mol Cell Biochem. 1997;166(1–2):65–71.
   PubMedGoogle Scholar
• Lin S, Zhang G, Liao Y, et al. Inhibition of chrysin on xanthine oxidase activity and its inhibition mechanism. Int J Biol Macromol. 2015;81:274–282.
   PubMed Web of Science ®Google Scholar
• Tang DH, Ye YS, Wang CY, et al. Potassium oxonate induces acute hyperuricemia in the tree shrew (Tupaia belangeri chinensis). Exp Anim. 2017;66(3):209–216.
   PubMed Web of Science ®Google Scholar
• Zhou QM, Zhao XY, Wang HG, et al. Mechanism and uric acid reducing effects of theaflavin on potassium oxonate-induced hyperuricemia in mice. Chin J New Drugs. 2018;27:1631–1638.
   Google Scholar
• Spiga R, Marini MA, Mancuso E, et al. Uric acid is associated with inflammatory biomarkers and induces inflammation via activating the NF-κB signaling pathway in HepG2 cells. Arterioscler Thromb Vasc Biol. 2017;37(6):1241–1249.
   PubMed Web of Science ®Google Scholar
• Liu J, Shen P, Ma X, et al. White blood cell count and the incidence of hyperuricemia: insights from a community-based study. Front Med. 2019;13(6):741–746.
   PubMedGoogle Scholar
• Su P, Hong L, Zhao Y, et al. The association between hyperuricemia and hematological indicators in a Chinese adult population. Medicine. 2016;95(7):e2822.
   PubMedGoogle Scholar